Response to the letter to the editor 'Reply to "Statistical controversies in clinical research: end points other than survival are vital for regulatory approval of anticancer agents" by H. K. van Halteren'

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/22824

Title:	Response to the letter to the editor 'Reply to "Statistical controversies in clinical research: end points other than survival are vital for regulatory approval of anticancer agents" by H. K. van Halteren'
Authors:	Saad, E. D. BUYSE, Marc
Issue Date:	2016
Publisher:	ELSEVIER
Source:	ANNALS OF ONCOLOGY, 27(8), p. 1653
Abstract:	6. Yoon SH, Kim KW, Goo JM, Kim DW, Hahn S. Observer variability in RECIST-based tumour burden measurements: a meta-analysis. Eur J Cancer 2016; 53: 5-15. 7. Marten K, Auer F, Schmidt S et al. Inadequacy of manual measurements compared to automated CT volumetry in assessment of treatment response of pulmonary metastases using RECIST criteria. Eur
Notes:	[Saad, E. D.; Buyse, M.] Int Drug Dev Inst, Louvain La Neuve, Belgium. [Saad, E. D.] Dendrix Res, Sao Paulo, Brazil. [Buyse, M.] Hasselt Univ, Interuniv Inst Biostat & Stat Bioinformat I BioSt, Diepenbeek, Belgium.
Document URI:	http://hdl.handle.net/1942/22824
ISSN:	0923-7534
e-ISSN:	1569-8041
DOI:	10.1093/annonc/mdw196
ISI #:	000383182800046
Rights:	© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Category:	A1
Type:	Journal Contribution
Validations:	ecoom 2017
Appears in Collections:	Research publications

File	Description	Size	Format
1-s2.0-S0923753419347349-main.pdf Restricted Access	Published version	52.6 kB	Adobe PDF	View/Open Request a copy

Check